Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
NCT02021825
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Neuromyelitis Optica
Neuromyelitis Optica Spectrum Disorders
Interventions
DRUG:
Mitoxantrone
Sponsor
Xuanwu Hospital, Beijing